FDA clears ACC's (Associates of Cape Cod's) fungal diagnostic:
This article was originally published in Clinica
The US FDA has given Associates of Cape Cod (ACC) clearance to market its serological assay for the qualitative detection of beta-glucan in patients with symptoms of, or medical conditions predisposing them to, invasive fungal infection, and as an aid in the diagnosis of deep-seated mycoses and fungemias. The Glucatell test measures (1,3)-beta-D-glucan, a fungal wall compound that is shed into the blood during fungal infections. In a recent study, the test resulted in a median of 12 days advance indication of fungal infection, as compared with conventional diagnostic procedures, claims the East Falmouth, Massachusetts firm, a wholly-owned subsidiary of Seikagaku.
You may also be interested in...
Arcadia prohibited from arguing against Advantice’s appeal of National Advertising Division decision that Kerasal Fungal Nail Renewal ad claims weren’t supported. Arcadia violated confidentiality rule by publicizing NAD decision before the review was officially closed.
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.
Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.